Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Organon's reported carbon emissions
In 2023, Organon reported significant carbon emissions from its operations in the UK, with Scope 1 emissions reaching approximately 2,272,000,000 kg CO2e and Scope 2 emissions at about 5,557,000,000 kg CO2e. The company also disclosed Scope 3 emissions, which totalled around 4,150,000,000 kg CO2e, encompassing various categories such as business travel and employee commuting. In 2022, Organon's emissions were similarly substantial, with Scope 1 emissions at approximately 1,122,000,000,000 kg CO2e and Scope 2 emissions (market-based) at about 5,677,000,000,000 kg CO2e. The Scope 3 emissions for that year were reported at around 1,029,000,000 kg CO2e. Despite these high emissions figures, Organon has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company operates within a challenging industry context, where pharmaceutical companies are increasingly scrutinised for their environmental impact and are expected to adopt more aggressive climate strategies. Overall, Organon's emissions data highlights the scale of its carbon footprint, particularly in the UK, while also reflecting the broader industry trend towards greater accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
